Searched for
OBESITY IN INDIA
Anupam Kher is 71 and fitter than ever. His every day food costs just Rs 80 a kg but ‘not very tasty’. Science says it can help lose weightVeteran actor Anupam Kher, aged 71, showcases remarkable fitness. A recent workout video went viral, impressing fans. Kher shared his diet,...- India makes gains in child, maternal health but nutrition challenges persist: SBI reportIndia's latest health survey reveals significant improvements in maternal care and child vaccination rates. Stunting among children has see...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Cipla appoints health chief Shivam Puri to lead One India businessCipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take...
- The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
- India risks becoming "unhealthier before it becomes richer," CEA V Anantha Nageswaran warnsIndia faces a health challenge before achieving wealth. Chief Economic Advisor V Anantha Nageswaran points to rising obesity and sedentary ...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- India's weight-loss market grows upThe landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block dealShares of Alkem Laboratories will be in focus after block deals worth around Rs 930 crore saw 17.88 lakh shares traded at Rs 5,200 apiece o...
- Time to walk and cycle the talk: Unsafe roads and broken footpaths are worsening India’s obesity crisisCommuting in Indian urban centers is riddled with obstacles, where inadequate sidewalks and hazardous road conditions push people towards c...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- 90.6% hospital births, 96% plus vaccinations: NFHS-6 reflects India's "accelerated progress" in family health parametersIndia's National Family Health Survey-6 shows significant improvements in maternal and child health. Vaccinations and antenatal care have i...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Dietary balance remains missing as India continues to gorge on cerealsMany Indians consume too many grains and not enough proteins, vegetables and fruits. This imbalance affects health, contributing to malnutr...
Load More
